ClinicalTrials.gg
RecruitingNCT05262907Updated Oct 23, 2025

Ventripoint Single Ventricle Study

An interventional study of Transthoracic Echocardiogram or Cardiac MRI and Ventripoint Echocardiogram in Congenital Heart Disease and Single-ventricle, sponsored by Duke University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Duke University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Planned enrollment
53rd of 184
100 · median 48
Started
2022
with 16 others
No phase
111 of 356
22 open now
Primary completion
2027-08
later than 44 of 86 live
Registered
287th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 53rd largest by planned enrollment of the 184 interventional ones that give a count, is one of 17 that started in 2022, is one of 111 with no phase, reaches primary completion later than 44 of the 86 other live ones, and was the 287th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.

Read the detailed description

The accuracy of current echocardiographic techniques for measuring ventricular size and function are limited by geometric assumptions, which are particularly problematic in malformed hearts or functional single ventricles, as well as the inability to visualize the entire heart at one time from a single imaging window, and higher heart rates degrading 3D imaging volume rates. This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles, including a comparison to the gold standard of cardiac MRI.

03

Conditions studied

  • Congenital Heart Disease
  • Single-ventricle
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with functional single ventricles will be included, regardless of age or surgical palliation stage, who have had or are having a clinically ordered transthoracic echocardiogram and/or cardiac MRI.

Exclusion criteria

Exclusion Criteria:

  • Patients with congenital heart disease other than functional single ventricles, patients with single ventricle physiology (but not single ventricle anatomy) following a biventricular conversion pathway, or patients unable to understand or consent in English will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Ventripoint 3D Echocardiogram

    Ventripoint 3D Echo performed on subject to validate technology for use in single ventricle patients.

    Device: Ventripoint Echocardiogram

  • Active comparator
    Transthoracic Echocardiogram or Cardiac MRI

    Non-invasive imaging of the heart to evaluate structure and function.

    Device: Transthoracic Echocardiogram or Cardiac MRI

Interventions

  • DeviceTransthoracic Echocardiogram or Cardiac MRI

    Non-invasive imaging of the heart to evaluate structure and function.

  • DeviceVentripoint Echocardiogram

    Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.

06

What researchers measure

Primary outcomes

  1. Cardiac function of the right ventricle as measured by ejection fraction

    Ejection Fraction (EF) is a measurement of the percentage of blood leaving your heart each time it squeezes (contracts)with each heart beat.

    Time frame: Day 1

  2. Cardiac function of the left ventricle as measured by ejection fraction

    Ejection Fraction (EF) is a measurement of the percentage of blood leaving your heart each time it squeezes (contracts)with each heart beat.

    Time frame: Day 1

  3. Right ventricular dimension as measured by end diastolic volume

    End Diastolic Volume (EDV) is the volume of blood in a ventricle at end load or filling in (diastole) or the amount of blood in the ventricles just before systole.

    Time frame: Day 1

  4. Right ventricular dimension as measured by end systolic volume

    End Systolic Volume (ESV) is the volume of blood in a ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.

    Time frame: Day 1

  5. Left Ventricular Dimension as measured by end diastolic volume

    End Diastolic Volume (EDV) is the volume of blood in a ventricle at end load or filling in (diastole) or the amount of blood in the ventricles just before systole.

    Time frame: Day 1

  6. Left Ventricular Dimension as measured by end systolic volume

    End Systolic Volume (ESV) is the volume of blood in a ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.

    Time frame: Day 1

  7. Left Ventricular Dimension as measured by end diastolic diameter

    End Diastolic Diameter (EDD) is the diameter across the left ventricle of the heart at the end of diastole, that is, when the heart muscle is maximally relaxed, and usually corresponds to its largest diameter.

    Time frame: Day 1

  8. Left Ventricular Dimension as measured by end systolic diameter

    End Systolic Diameter (ESD) is the diameter across the left ventricle of the heart at the end of systole, that is, when the heart muscle is maximally contracted, and usually corresponds to its smallest diameter.

    Time frame: Day 1

  9. Right Ventricular Function as measured by tricuspid annular plane systolic excursion

    Tricuspid Annular Plane Systolic Excursion (TAPSE) is a measurement of the decent of the right ventricular base towards a relatively fixed apex.

    Time frame: Day 1

  10. Right Ventricular Function as measured by myocardial performance index

    RV Myocardial Performance Index (MPI) is a measurement that incorporates tricuspid valve closure to opening time and right ventricular ejection time to evaluate efficiency of the ventricle.

    Time frame: Day 1

  11. Left Ventricular Function as measured by myocardial performance index

    LV Myocardial Performance Index (MPI) is a measurement that incorporates mitral valve closure to opening time and left ventricular ejection time to evaluate efficiency of the ventricle.

    Time frame: Day 1

  12. Left Ventricular Function as measured by tissue doppler imaging

    Tissue Doppler Imaging (TDI) a measurement of the velocity of myocardial motion.

    Time frame: Day 1

  13. Left ventricular function as measured by shortening fraction

    Shortening fraction(SF) is a measurement of the percentage of change in left ventricular diameter during systole.

    Time frame: Day 1

  14. Presence of ventricular dysfunction as measured by strain

    Strain is a measure of deformity in the muscle of the ventricle.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 61 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 61 months is above that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 2, 2022
StartActual
Jul 8, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05262907
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Jul 8, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 23, 2025

Study contacts

Joan Wilson
Contact
joan.wilson@duke.edu
999999999
Piers Barker, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion